Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. ​ Recent advancements in the understanding and management of MM have led to significant improvements in patient outcomes. ​ The diagnosis of MM is based on the presence of monoclonal plasma cells, monoclonal protein, and myeloma-related organ and tissue impairment, including bone lesions. ​ New technologies, such as cytogenetic analysis and molecular profiling, have enhanced the evaluation of the biology and extent of the disease. ​

Treatment for MM depends on factors such as eligibility for high-dose therapy and stem cell transplantation. ​ Bisphosphonates play a crucial role in the management of bone disease associated with MM, reducing skeletal-related events and improving quality of life. Common complications in MM include infections, renal failure, anemia, venous thromboembolic events (VTEs), and polyneuropathy, which require prompt and targeted management. ​ Pain management in MM should be tailored to the specific cause and grade of pain, utilizing analgesics, bisphosphonates, and radiation therapy as appropriate. ​

Supportive care measures, including hydration, blood transfusions, and growth factors, are essential in managing the complications of MM. Novel targeted therapies, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, have revolutionized the treatment landscape for MM. Combination regimens incorporating these novel agents have shown significant improvements in response rates, progression-free survival, and overall survival. Maintenance therapy with lenalidomide or bortezomib has demonstrated the ability to prolong remission and improve outcomes in eligible patients.​

Relapsed or refractory MM remains a challenge, but new effective agents, including carfilzomib and pomalidomide, offer promise in this setting. ​ Palliative treatment options, such as alkylating agents, corticosteroids, and older regimens, may be considered for patients with refractory disease. ​ Allogeneic stem cell transplantation is reserved for highly selected patients in the context of clinical trials or experienced centers. ​

Ongoing research and clinical trials continue to explore new treatment strategies and improve outcomes for patients with MM. ​ The multidisciplinary approach, incorporating novel therapies, supportive care measures, and personalized treatment plans, is essential in optimizing the management of MM and improving patient outcomes.

Important Points:

1. Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal plasma cell proliferation in the bone marrow. ​
2. Diagnosis of MM is based on the presence of monoclonal plasma cells, monoclonal protein, and myeloma-related organ and tissue impairment, including bone lesions. ​
3. Recent advancements in technology, such as cytogenetic analysis and molecular profiling, have improved the evaluation of MM biology and extent. ​
4. Treatment for MM depends on eligibility for high-dose therapy and stem cell transplantation. ​
5. Bisphosphonates are essential in managing bone disease associated with MM, reducing skeletal-related events and improving quality of life.
6. Common complications in MM include infections, renal failure, anemia, venous thromboembolic events (VTEs), and polyneuropathy. ​
7. Prompt and targeted management is required for complications in MM, including appropriate antimicrobial prophylaxis and supportive care measures. ​
8. Pain management in MM should be tailored to the specific cause and grade of pain, utilizing analgesics, bisphosphonates, and radiation therapy as appropriate. ​
9. Supportive care measures, such as hydration, blood transfusions, and growth factors, are crucial in managing MM complications.
10. Novel targeted therapies, including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, have revolutionized MM treatment.
11. Combination regimens incorporating novel agents have shown significant improvements in response rates, progression-free survival, and overall survival.
12. Maintenance therapy with lenalidomide or bortezomib has demonstrated the ability to prolong remission and improve outcomes in eligible patients. ​
13. Relapsed or refractory MM remains a challenge, but new effective agents, such as carfilzomib and pomalidomide, offer promise. ​
14. Palliative treatment options, including alkylating agents, corticosteroids, and older regimens, may be considered for patients with refractory disease. ​
15. Allogeneic stem cell transplantation is reserved for highly selected patients in the context of clinical trials or experienced centers. ​
16. Ongoing research and clinical trials continue to explore new treatment strategies and improve outcomes for MM patients. ​
17. A multidisciplinary approach, incorporating novel therapies, supportive care measures, and personalized treatment plans, is crucial in optimizing MM management and improving patient outcomes.

Authors:

Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B.

Citation:

Leukemia. 2014 May;28(5):981-92.
doi: 10.1038/leu.2013.293. Epub 2013 Oct 9.